Activist investor Glenview Capital said on Tuesday it had reduced its holdings in CVS Health following the insurer's "healthy ...

CVS Health (NYSE:CVS) reported robust year-over-year growth in Q1 2025 earnings, with significant increases in sales, revenue ...

CVS Health sees strong Q1 2025 growth, but risks loom with downgraded revenue guidance and Medicare challenges. Read my ...

CVS Health Corp. reported a strong start to 2025, with first-quarter revenue climbing 7%, driven by growth across all business segments.

Retail sales of passenger vehicles (PV) grew 1.5% year-on-year to 3.5 lakh units in April 2025 compared with 3.44 lakh units ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Cigna posts strong Q1 results with rising sales at Evernorth and Cigna Healthcare; raises 2025 EPS outlook to $29.60 amid ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Knorr-Bremse reported a strong order intake of €2.376 billion, which outpaced the consensus estimate of €2.066 billion. The Rail Vehicle Systems (RVS) orders surpassed expectations by 13%, while ...

CVS Health Corp posted a strong first quarter in 2025, with earnings per share (EPS) of $2.25, surpassing the forecast of $1.64 ... and innovations are driving growth. CVS Health demonstrated ...